Poniard Pharmaceuticals (Poniard Pharmaceuticals) EPS (Diluted) : $-12.00 (TTM As of Sep. 2011)

Poniard Pharmaceuticals EPS (Diluted) Chart

Poniard Pharmaceuticals Annual Data
	Trend	Dec01	Dec02	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10
EPS (Diluted)		Get a 7-Day Free Trial					-54.80	-43.20	-56.40	-52.40	-26.40

Poniard Pharmaceuticals Quarterly Data
	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11
EPS (Diluted)	Get a 7-Day Free Trial															-5.20	-4.40	-2.40	-2.80	-2.40

Competitive Comparison of Poniard Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Poniard Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's PE Ratio falls into.

Poniard Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Poniard Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2010 is calculated as

Poniard Pharmaceuticals's Diluted EPS for the quarter that ended in Sep. 2011 is calculated as

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals  (OTCPK:PARD) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Poniard Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description